caa a22 4500 469118792 CHVBK 20180323133132.0 cr unu---uuuuu 170328e19921201xx s 000 0 eng 10.1007/BF02247721 doi (NATIONALLICENCE)springer-10.1007/BF02247721 Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) [Elektronische Daten] [Charanjit Aulakh, James Hill, Hakan Yoney, Dennis Murphy] Administration of various doses of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) to rats produced dose-related decreases in 1-h food intake in the food-deprived paradigm. Pretreatment with spiperone (5-HT1A/5-HT2/D2 antagonist), propranolol or CGP361A (β-adrenoceptor antagonists that also have binding affinities for 5-HT1A and 5-HT1B sites) and MDL-72222 (5-HT3 antagonist) did not attenuate DOI-induced suppression of food intake. In contrast, pretreatment with metergoline (5-HT1/5-HT2 antagonist) completely blocked whereas mesulergine, mianserin and ritanserin (5-HT1C/5-HT2 antagonists) partially blocked DOI's effect on food intake. On the other hand, pretreatment with MDL-72222 but not with m-chlorophenylpiperazine (m-CPP) significantly potentiated DOI-induced suppression of food intake. Furthermore, the food intake suppressant effects of various doses of DOI were found to be similar in the Fawn-Hooded (FH) rat strain as compared to the Wistar rat strain. These findings suggest that DOI-induced suppression of food intake is mediated by stimulation of both 5-HT1C and 5-HT2 receptors. Springer-Verlag, 1992 Metergoline nationallicence Mesulergine nationallicence Mianserin nationallicence Spiperone nationallicence MDL-72222 nationallicence Propranolol nationallicence Food-deprived nationallicence Ritanserin nationallicence Aulakh Charanjit Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut Hill James Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut Yoney Hakan Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut Murphy Dennis Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut Psychopharmacology Springer-Verlag 109/4(1992-12-01), 444-448 0033-3158 109:4<444 1992 109 213 https://doi.org/10.1007/BF02247721 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247721 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Aulakh Charanjit Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Hill James Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Yoney Hakan Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Murphy Dennis Laboratory of Clinical Science, National Institute of Mental Health, Clinical Center, 9000 Rockville Pike, 20892, Bethesda, MD, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/4(1992-12-01), 444-448 0033-3158 109:4<444 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer